Skip to main content

Advertisement

SpringerLink
Log in

Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Standard therapeutic options for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified (PTCL—NOS) remain unclear. There are few large cohort studies specifically focused on gemcitabine-based chemotherapy for PTCL—NOS. We retrospectively reviewed patients with relapsed or refractory PTCL—NOS who received salvage GDP (gemcitabine, dexamethasone, and cisplatin) chemotherapy at the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China, from May 2008 to August 2014. Twenty-five patients were enrolled and analyzed. The median number of cycles of GDP chemotherapy per patient was four (range, 2–8 cycles). Overall response rate was 64.0% (16/25) with five achieved complete remission or complete remission unconfirmed. After a median follow-up of 9 months, median overall survival (OS) and progression-free survival after relapse or progression (second-PFS) were 9.3 and 5.4 months. One-year PFS rate and 1-year OS rate were 27.4% and 43.9%, respectively. Median second-PFS was significantly longer in patients sensitive to GDP than the ones resistant to the treatment (10.3 vs. 2.8 months, p < .01). In addition, the low International Prognostic Index, low Prognostic Index for T cell lymphoma, or normal level of LDH in serum was associated with favorable prognosis. Grade 3/4 adverse effect was observed in 10 of 25 patients treated with GDP including neutropenia (8/25), thrombocytopenia (5/25), and anemia (4/25). Taken together, our study suggests that GDP is an effective and optional salvage regimen for relapsed or refractory PTCL—NOS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26:4124–4130

    Article  Google Scholar 

  2. Briski R, Feldman AL, Bailey NG et al (2014) The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood cancer journal 4:e214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ (2011) A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN hematology 2011:623924

    Article  PubMed  PubMed Central  Google Scholar 

  4. Armitage JO (2013) The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol 88:910–918

    Article  PubMed  Google Scholar 

  5. Coiffier B, Federico M, Caballero D et al (2014) Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev 40:1080–1088

    Article  CAS  PubMed  Google Scholar 

  6. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K (2011) Peripheral T-cell lymphoma. Blood 117:6756–6767

    Article  CAS  PubMed  Google Scholar 

  7. Kinoshita T (2014) Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Nihon rinsho Japanese journal of clinical medicine 72:512–518

    PubMed  Google Scholar 

  8. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 17:1244

    CAS  Google Scholar 

  9. Gallamini A, Stelitano C, Calvi R et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479

    Article  CAS  PubMed  Google Scholar 

  10. Weisenburger DD, Savage KJ, Harris NL et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402–3408

    Article  CAS  PubMed  Google Scholar 

  11. Reimer P (2010) Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Advances in hematology 2010:320624

    Article  PubMed  PubMed Central  Google Scholar 

  12. Yared J, Kimball A (2013) The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 39:51–59

    Article  CAS  PubMed  Google Scholar 

  13. Zain JM, O'Connor O (2010) Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 92:33–44

    Article  CAS  PubMed  Google Scholar 

  14. Zinzani PL, Venturini F, Stefoni V et al (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 21:860–863

    Article  CAS  Google Scholar 

  15. Yim KL, Ashley S (2012) Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. Medical oncology (Northwood, London, England) 29:3535–3539

    Article  CAS  Google Scholar 

  16. Arkenau HT, Chong G, Cunningham D et al (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92:271–272

    Article  CAS  PubMed  Google Scholar 

  17. Yao YY, Tang Y, Zhu Q et al (2013) Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leukemia & lymphoma 54:1194–1200

    Article  CAS  Google Scholar 

  18. Mahadevan D, Unger JM, Spier CM et al (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371–379

    Article  CAS  PubMed  Google Scholar 

  19. Dong M, He XH, Liu P et al (2013) Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Medical oncology (Northwood, London, England) 30:351

    Article  Google Scholar 

  20. Park BB, Kim WS, Suh C et al (2015) Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol 94:1845–1851

    Article  CAS  PubMed  Google Scholar 

  21. Mak V, Hamm J, Chhanabhai M et al (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31:1970–1976

    Article  CAS  Google Scholar 

  22. O'Connor OA, Pro B, Pinter-Brown L et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29:1182–1189

    Article  Google Scholar 

  23. Zinzani PL, Alinari L, Tani M et al (2005) Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90:702–703

  24. Shi Y, Dong M, Hong X et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 26:1766–1771

    Article  CAS  Google Scholar 

  25. Coiffier B, Pro B, Prince HM et al (2014) Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 7:11

    Article  PubMed  PubMed Central  Google Scholar 

  26. O'Connor OA, Horwitz S, Masszi T et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33:2492–2499

    Article  Google Scholar 

  27. Foss F, Advani R, Duvic M et al (2015) A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 168:811–819

    Article  CAS  PubMed  Google Scholar 

  28. Morschhauser F, Fitoussi O, Haioun C et al (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. European journal of cancer (Oxford, England : 1990) 49:2869–2876

    Article  CAS  Google Scholar 

  29. Damaj G, Gressin R, Bouabdallah K et al (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31:104–110

    Article  CAS  Google Scholar 

  30. Pellegrini C, Dodero A, Chiappella A et al (2016) A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. J Hematol Oncol 9:38

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Our study was unfunded. We thank all doctors and nurses of the department of medical oncology as well as the department of pathology and radiology for their help in realization of this study.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China

    Fei Qi, Mei Dong, Xiaohui He, Peng Liu, Jianliang Yang, Lin Gui, Changgong Zhang, Sheng Yang, Shengyu Zhou & Yuankai Shi

  2. Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

    Yexiong Li & Weihu Wang

Authors
  1. Fei Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mei Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaohui He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yexiong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weihu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianliang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lin Gui
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Changgong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sheng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shengyu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yuankai Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mei Dong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qi, F., Dong, M., He, X. et al. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified. Ann Hematol 96, 245–251 (2017). https://doi.org/10.1007/s00277-016-2877-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2877-6

Keywords

Search

Navigation